Search Results

<< Back Pancreatic NET (PNET) Insulinoma upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism PRRT/RLT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine (GEP-NETs) Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs COMPOSE (GEP-NETS) ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients Oral Treatment SWOG S2104: Adjuvant CAPTEM for High Risk pNET Belzutifan/MK-6482 in PNET + PPGL + VHL CDK4/6 Abemaciclib Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers SORENTO™: Subcutaneous Octreotide for GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) SORENTO™: Subcutaneous Octreotide for GEP-NETs STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Research / Clinical Trials < Back to Topics Latest News on Clinical Trials Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Play Video Play Video 03:51 Update: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors Load More Educational Videos on Research / Clinical Trials Educational Content on Research/Clinical... Play Video Play Video 01:29:26 The Latest in Neuroendocrine Cancer Clinical Trials • 2026 NCF Event • Feb 20, 2026 Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation focuses on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources. Visit the event page at https://www.ncf.net/events/feb2026 Play Video Play Video 27:02 9. The Future of NETs: Emerging Therapies & Clinical Trials • Dr. Aman Chauhan •2025 NET Cancer Day Dr. Aman Chauhan speaks about "The Future of NETs: Emerging Therapies & Clinical Trials" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 18:44 1. Demystifying Clinical Trials • Taymeyah Al-Toubah • 2025 NET Cancer Day Symposium Taymeyah Al-Toubah speaks on "Demystifying Clinical Trials" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 14:04 15. What Matters About Clinical Trials • Pamela Kunz, MD • @NCFCancer "What Matters About Clinical Trials" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Pamela Kunz, MD Medical Oncologist Yale Medicine @NCFCancer Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 33:12 "The Future of NETs: Evolving Treatments & Clinical Trials" • Jaydira Del Rivero, MD • 2024 "The Future of NETs: Evolving Treatments & Clinical Trials" with Jaydira Del Rivero, MD, Medical Oncologist/Endocrinologist, National Cancer Institute/National Institutes Of Health at the 2024 NET Cancer Day Symposium. Play Video Play Video 15:17 "The Latest in NET Medical Therapies" • Andrew Hendifar, MD, Cedars Sinai • 2024 NET Cancer Day Andrew Hendifar, MD, Medical Oncologist, Cedars Sinai, talks about the latest in NET medical therapies at the 2024 NET Cancer Day Symposium. Play Video Play Video 16:36 10. Clinical Trials: The Latest & Greatest • Pamela Kunz, MD • @NCFCancer Play Video Play Video 28:41 Clinical Trials 101/Opportunities to Access NET Resources&Trials • Del Rivero MD • 2023 NETCancerDay Clinical Trials 101/Opportunities to Access NET Resources&Trials • Del Rivero MD • 2023 NET Cancer Day Symposium • Santa Monica, CA • @NCFCancer Speaker: Jaydira Del Rivero, MD Medical Oncologist Endrocrinologist National Cancer Institute, NIH For more information, visit LACNETS.org Load More In Depth Look at Active Clinical Trials In Depth Look: Active Clinical Trials Play Video Play Video 06:46 (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET • ClinicalTrials.gov ID: NCT06943755 Dr. Aman Chauhan discusses (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors. Visit https://www.ncf.net/clinical-trials for more information. Play Video Play Video 14:15 Tarlatamab in DLL3-Expressing Tumors Including NEN • ClinicalTrials.gov: NCT06788938 • Dr. Goldman Join Dr. Jonathan Goldman, medical oncologist and clinical trial specialist at UCLA, as he provides an in-depth overview of a new clinical trial investigating tarlatumab, a DLL3-targeted bispecific T-cell engager designed to treat a wide range of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this talk, Dr. Goldman explains: - What DLL3 is and why it is an important target found on many neuroendocrine tumors - How tarlatumab works by connecting T-cells to tumor cells to trigger a focused immune response - Why DLL3-positive tumors—including small cell lung cancer, lung carcinoids, thymic tumors, pancreatic NETs, gastrointestinal NETs, prostate NEC, Merkel cell carcinoma, and others—may respond to this therapy - The structure of the L10 Clinical Trial, now in Stage 2 and enrolling across all University of California cancer centers - What patients can expect from the tarlatumab treatment schedule and dosing - Potential side effects such as cytokine release syndrome, fatigue, constipation, loss of taste, neurologic symptoms, and tumor lysis syndrome Dr. Goldman highlights both the promise of DLL3-targeted therapies and the ongoing need to understand how DLL3 expression levels relate to patient response. For more information, visit https://www.ncf.net/clinical-trials-1/tarlatamab Play Video Play Video 13:57 A Study of ZL-1310 in Participants With Selected Solid Tumors • ClinicalTrials.gov ID: NCT06885281 Dr. Rohit Thummalapalli discusses "A Study of ZL-1310 in Participants With Selected Solid Tumors" (ClinicalTrials.gov ID: NCT06885281). For more information, visit NCF.net/clinical-trials Play Video Play Video 06:54 (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen•NCT07087054 Dr. Aman Chauhan discusses (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (ClinicalTrials.gov: NCT07087054). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 08:57 Study of 225Ac-ABD147 to Establish Optimal Dose • ClinicalTrials.gov: NCT06736418 • Dr. Chauhan Dr. Aman Chauhan discusses the Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy (ClinicalTrials.gov: NCT06736418). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 12:34 May 19, 2025: Dr. Aman Chauhan discusses the DAREON-5 & DAREON-7 Studies DAREON-5 is a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. This is a clinical trial for high grade neuroendocrine cancers. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. The study is sponsored by Boehringer Ingelheim. For more information, visit https://www.lacnets.org/clinical-trials-1/dareontm--5%3A-dll-3-bite-for-neuroendocrine-cancers. Play Video Play Video 16:57 SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated NEC or Well-Differentiated High-Grade NET Dr. Aman Chauhan at the Sylvester Comprehensive Cancer Center, University of Miami, discusses SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) tumors. Recorded: April 22, 2025 For more information, visit https://www.ncf.net/clinical-trials-1/svv-001 Play Video Play Video 29:35 IL13Rα2 CAR T Cell Study for Solid Tumor Cancers • Dr. Anusha Kalbasi Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024. For more information about this trial, visit https://www.lacnets.org/clinical-trials-1/il13r%CE%B12-car-t-cell-study-for-solid-tumor-cancers. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 05:10 Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC • Dr. Aman Chauhan Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC. Recorded: June 20, 2024 Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Load More Patient Stories: Clinical Trials Patient Stories: Clinical Trials Play Video Play Video 04:08 Patient Story: NET Patient shares about her experience in a clinical trial (LACNETS) NET Patient Mary shares about her experience in a clinical trial (Everolimus or Afinitor). November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 21:23 NET Clinical Trial: An Oral Somatostatin Analogue in Patients with Carcinoid Syndrome - Jan 2024 Crinetics is sponsoring a clinical trial to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment, an oral (pill) somatostatin analogue in patients with carcinoid syndrome. Learn more about the trial and inclusion criteria here. This trial is currently open at Hoag Cancer Center in Newport Beach, California with Dr. Michael Demeure. If interested, contact Clinical Research Nurse Coordinator Jericho Rabago via direct line 949-764-6796 or email Jericho.Rabago@hoag.org. Learn about more clinical trials here: lacnets.org/clinical-trials Play Video Play Video 07:10 Patient Story: NET Patient shares her experience with Alpha PRRT NET Patient DeAnne shares her experience with Alpha PRRT. March 16th, 2021 To learn more about the LACNETS , visit www.LACNETS.org. < Back to Topics Next Topic >

< Back to the upcoming events page Back to NCD Symposium Page 2025 NET Cancer Day Symposium Speakers Taymeyah Al-Toubah, MPH, CCRP FlaNET, Medical Student I hold dual bachelor’s degrees in Biomedical Sciences and Psychology (2015) and a Master of Public Health in Epidemiology (2017). Since 2013, I have worked in academic medicine and clinical research, beginning with neonatology and pediatrics before transitioning to phase I oncology in 2016. My interest in neuroendocrine tumors (NETs) began during my MPH thesis, which became one of my first NET publications. From 2018–2023, I served as the primary NET coordinator at Moffitt Cancer Center, managing all clinical trials, leading the GI team, and driving retrospective and non-interventional research. In 2023, I transitioned to Senior Project Manager of the NET program, overseeing protocol development, database creation, and manuscript writing, while curating a master database of more than 10,000 NET patients. After nearly a decade at Moffitt, I concluded my tenure in September 2025 to begin medical school in Italy the following month. I have published more than 45 manuscripts and delivered oral presentations at both ENETS and NANETS. Beyond institutional research, I serve on the Board of Directors of NANETS (now in my second year) and on the board of FLaNET Carcinoid Community. I also actively mentor three students in neuroendocrine tumor research: two undergraduate pre-medical students and a high school prodigy pursuing mathematical oncology and AI. In July 2025, I launched TayTalks , a podcast exploring professional growth, medicine, and life. Looking ahead, I am eager to combine my research foundation, medical training, and passion for advocacy to advance the care of NET patients as a future physician-scientist. Aman Chauhan, MD Medical Oncologist Sylvester Comprehensive Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. Tracy Crane, PhD, RDN Medical Oncology Sylvester Cancer Center Dr. Tracy E. Crane is an internationally recognized thought leader in cancer prevention and control, specializing in digital health interventions to improve patient outcomes. She is an Associate Professor of Medical Oncology, Public Health, and Kinesiology at the University of Miami and Co-Leader of the Cancer Control Research Program at Sylvester Comprehensive Cancer Center. As Director of Lifestyle Medicine, Prevention, and Digital Health, she leads a multidisciplinary research team focused on innovative lifestyle interventions, leveraging AI-driven technology to deliver precision behavioral strategies. In the last 5 years, she has secured over $30 million in research funding, including multiple National Cancer Institute (NCI)-funded studies and a large PCORI-funded trial, and has authored over 100 peer-reviewed publications, including co-authoring the latest American Cancer Society guidelines on nutrition and physical activity for cancer survivors. A registered dietitian with a Ph.D. in Nursing Science, Dr. Crane also serves as Chair for Cancer Prevention and Control nationally for NRG Oncology’s NCI Community Oncology Research Program. Her pioneering contributions have made her a sought-after speaker and leader in the global effort to integrate digital health and personalized lifestyle medicine into cancer prevention and care. Jashodeep Datta, MD Surgical Oncologist Sylvester Comprehensive Cancer Center Dr. Datta is the DiMare Family Endowed Chair in Immunotherapy, Associate Professor of Surgery, and a hepatobiliary and pancreatic surgical oncologist at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center. He is also a surgeon-scientist studying myeloid immunobiology in the pancreatic cancer microenvironment and novel ways to deploy immunotherapy in this disease. At Sylvester, he serves as the Assistant Director of Transdisciplinary Research, and Co-Leader of the Gastrointestinal Oncology Service Line at Sylvester where his mission is to augment the portfolio of investigator-initiated clinical trials offered in GI cancers. He is also the Associate Director of Translational Research at the Sylvester Pancreatic Cancer Research Institute. Dr. Datta joined the faculty at the University of Miami Miller School of Medicine in 2019. He graduated Summa cum Laude from Colgate University in Hamilton, NY and attended Vanderbilt University School of Medicine in Nashville, TN where he earned his MD and was inducted in the Alpha Omega Alpha (AOA) National Honor Society. He completed his residency in General Surgery at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA, during which he completed a post-doctoral research fellowship in cancer immunology. He subsequently completed a fellowship in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center, where he focused on surgical management of hepatobiliary, pancreatic, and gastric malignancies and developed expertise in computational immunogenomics. Since starting at Sylvester, his research has been extensively funded by the Miami Clinical and Translational Science Institute with an NIH KL2 award, American College of Surgeons’ Franklin H. Martin Research Fellowship, Association for Academic Surgery Joel J. Roslyn Faculty Award, Society for Surgical Oncology Young Investigator Award, the Elsa U. Pardee Foundation, the Pancreatic Cancer Action Network Career Development Award, the Department of Defense Pancreatic Cancer Research Program (PCARP), the V Foundation for Cancer Research, and the National Cancer Institute. His work has been recognized by multiple awards, including the Joan L and Julius H Jacobson II Promising Investigator Award from the American College of Surgeons, and an American Society of Clinical Investigation Young-Physician Scientist Award. Udhayvir Singh Grewal, MD Medical Oncologist Emory University School of Medicine Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. Boris Naraev, MD, PhD, FACP Medical Oncologist Tampa General Hospital Cancer Institute Dr. Naraev is a board-certified medical oncologist at the Tampa General Hospital’s Cancer Institute specializing in caring for people living with neuroendocrine and endocrine tumors. He is an Associate Professor of Medicine at the Division of Hematology and Medical Oncology of University of South Florida, Morsani College of Medicine. Prior to joining the TGH Cancer Institute, he was the Lead of Neuroendocrine Cancer Program at Banner MD Anderson Cancer Center in Phoenix, Arizona and Adjunct Assistant Professor with the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. While in Phoenix, he helped create, develop, and lead one of the largest neuroendocrine cancer programs in the Southwestern United States, and was personally taking care of a large population of patients with neuroendocrine tumors. Later, he served as the Leader of Gastrointestinal, Neuroendocrine, and Rare Cancers Program at the Anderson Family Cancer Institute at Jupiter Medical Center in Jupiter, Florida. In this capacity, he helped build the National Pancreas Foundation Pancreatic Cancer Center of Excellence at Jupiter Medical Center. He received his Doctor of Medicine degree from Orenburg State Medical Academy in Orenburg, Russia. Subsequently, he obtained PhD in Medical Sciences degree from the same institution. After completion of Internal Medicine residency training at St. Luke's Hospital in Chesterfield, Missouri, he proceeded to complete Hematology/Oncology Fellowship at the University of Iowa Hospitals and Clinics in Iowa City, Iowa. During his fellowship training, he developed a special interest in neuroendocrine tumors and completed several research projects in this field. Dr. Naraev is involved in neuroendocrine tumors related research and community outreach, and is a member of the NETPact Committee and Co-Chair of Guidelines Committee of the North American Neuroendocrine Tumor Society. Estelamari Rodriquez, MD, MPH Clinical Research Lead Thoracic Site Disease Group Associate Director for Community Outreach Sylvester Cancer Center Dr. Estelamari Rodriguez is Co-Lead of the Thoracic Site Disease Group and Associate Director of Community Outreach and of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is an active member of the Sylvester Experimental Therapeutics Program and has served as principal investigator of several early phase and cooperative group clinical trials in the United States. Dr. Rodriguez is a member of the ECOG Thoracic Committee and Chair-elect of the ASCO Evidence Based Medicine Committee. She has active advocacy roles as part of the board of the American Cancer Society- Cancer Action Network, the Miami Dade County Medical Association and Florida Society of Clinical Oncology (FLASCO). Dr. Rodriguez received her bachelor's degree from Columbia College and her medical degree from State University of New York (SUNY) Downstate College of Medicine. She completed her internal medicine residency at Columbia University’s New York-Presbyterian Hospital and her medical oncology fellowship at the University of Pennsylvania. Dr. Rodriguez also has a master’s degree in Public Health from the Universidad Autonoma de Madrid, Spain. She has given numerous international lectures as an invited speaker on issues related to lung cancer treatment and healthcare disparities. Jason Starr, DO Hematologist / Oncologist Mayo Clinic Dr. Starr grew up in South Florida and earned his medical degree at Lake Erie College of Osteopathic Medicine in Bradenton, Florida. He did his training at Mayo Clinic School of Graduate Medical Education in Jacksonville, where he completed his internship and residency in internal medicine, followed by a hematology/oncology fellowship. Dr. Starr has developed an expertise in treating gastrointestinal malignancies and has co-authored papers and book chapters on the subject. He has a special interest in neuroendocrine tumors and is committed to advancing the field through clinical research, namely through the development and enrollment of clinical trials. Dr. Starr is also passionate about education and is integrally involved with fellow education and well-being. He is board certified in internal medicine, hematology, and oncology. "The greatest joy of my career is the interaction and relationships I am able to have with my patients," says Dr. Starr. In his free time he enjoys and values spending time with his wife and children. He also enjoys exercise for fitness and stress relief. Dr. Starr is proud of his Mayo roots and feels strongly about Mayo Clinic's conviction to hope, faith, and science. Lindsay Thornton, MD Interventional Radiologist Sylvester Cancer Center Dr. Lindsay Thornton, M.D., is an Assistant Professor of Clinical Interventional Radiology at the University of Miami Miller School of Medicine. She specializes in interventional oncology, with a focus on hepatocellular carcinoma (HCC), metastatic colorectal cancer, neuroendocrine cancer, and uveal melanoma. She is highly skilled in transradial techniques for liver cancer treatments, uterine fibroid therapy, and other intra-arterial procedures. Dr. Thornton earned her medical degree from the University of Vermont, followed by an Internal Medicine internship at Rutgers-University Hospital. She then completed her Diagnostic Radiology residency at the University of Florida, where she served as Chief Resident of Research. She also was elected Clinical Education Chair for the Society of Interventional Radiology’s (SIR) RFS section from 2016-2017. She received the Excellence in Interventional Radiology Award in 2018 from UF and went on to complete her fellowship in Vascular and Interventional Radiology at Mount Sinai Icahn School of Medicine in 2019. She is board-certified in both Diagnostic and Interventional Radiology. Passionate about the disease process and treatment of HCC and clinical research, Dr. Thornton primarily studies locoregional therapies for HCC and co-chairs the Hepatocellular Operations Working Group with Dr. Patricia Jones since 2019. She has published in peer-reviewed journals and presented at national conferences. She also serves on the Interventional Oncology Service Line Committee for SIR (2023-current). An ardent advocate for quality, safety, and process improvement, Dr. Thornton is committed to enhancing patient care and streamlining clinical workflows. Her joy as a physician stems from ensuring high quality, personal care. She has served as Director of Quality, Safety, and Operations in Interventional Radiology at Jackson Memorial Hospital for the past three years. In 2023 she received the UM/JHS Quality and Safety Faculty Showcase Award. Back to NCD Symposium Page

SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Chemotherapy for NEC << Back SWOG S2012 - Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung CLINICALTRIALS.GOV IDENTIFIER: NCT05058651 DRUG/TREATMENT: Atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) PHASE: II/III STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=3YGASJXkSxI Dr. David Zhen Discusses SWOG S2012 Immunotherapy (atezolizumab) DESCRIPTION: This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here . CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. Principal Investigator: David B. Zhen, MD Southwest Oncology Group

DAREON™-7: DLL3 for Advanced Neuroendocrine Cancers << Back DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT06132113 DRUG/TREATMENT : BI 764532, Carboplatin, Etoposide, Cisplatin PHASE : 1 STATUS : Recruiting SPONSOR : Boehringer Ingelheim https://www.youtube.com/watch?v=tSN7eS8fJPw DESCRIPTION: This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3. The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has 2 parts. Part A of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researchers also want to find out whether BI 764532 in combination with chemotherapy helps people with NEC. Participants get different doses of BI 764532 as an infusion into a vein. In addition, they get platinum-based chemotherapy as infusions into a vein. Participants can continue treatment up to 3 years if they benefit from treatment and can tolerate it. Participants visit their doctors regularly. During these visits, the doctors collect information about participants' health and take note of any unwanted effects. Doctors also regularly check the size of the tumour. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Boehringer Ingelheim EMAIL: clintriage.rdg@boehringer-ingelheim.com PHONE: 1-800-243-0127 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. OTHER HELPFUL RESOURCES:

CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen << Back CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen IDENTIFIER ( ClinicalTrials.gov ) : NCT07087054 DRUG/TREATMENT : Paltusotine PHASE : 3 STATUS : Recruiting SPONSOR : Crinetics Pharmaceuticals Inc. https://www.youtube.com/watch?v=b6Jnzj9Epng CAREFNDR Presentation Slides .pdf Download PDF • 1.60MB DESCRIPTION: A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. MORE INFORMATION Download the CAREFNDR flyer here >>> For more information about the CAREFNDR clinical study, visit CAREFNDR.com/ncf . Global enrollment in CAREFNDR is expected throughout 2025 and 2026. Read this recent press release: " Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome" CONTACT Crinetics Clinical Trials EMAIL: clinicaltrials@crinetics.com PHONE: 833-276-4636 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Go back to the Podcast page EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES Download the transcript here: LACNETS Podcast Episode 27 Transcript .pdf Download PDF • 206KB ABOUT THIS EPISODE What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr. Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. MEET DR. XAVIER KEUTGEN Xavier M. Keutgen MD is a board-certified, double-fellowship trained surgeon who specializes in the treatment of gastro, entero, pancreatic neuroendocrine tumors and neoplasms of the thyroid, parathyroid and adrenal glands. A native from Belgium, Dr. Keutgen graduated magna cum laude from the University of Heidelberg Medical School in Germany and completed a general surgery residency and surgical oncology research fellowship at New York Presbyterian Hospital-Weill Cornell Medical Center. He then completed a hepato-pancreato-biliary fellowship at the University Hospital of Zurich in Switzerland as well as an endocrine oncology and surgery fellowship at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Keutgen currently serves as the director of the Neuroendocrine Tumor Program, director of the Endocrine Research Program and co-director of the Von Hippel-Lindau Clinical Care Program at the University of Chicago Medicine . Throughout his career Dr. Keutgen has developed a particular interest in clinical, translational and basic science research. His laboratory specializes in investigating the role of radiation therapy and DNA damage repair in pancreatic, lung and small bowel neuroendocrine tumors, discovering new actionable molecular targets for neuroendocrine tumors, and elucidating new mechanisms of drug delivery for endocrine malignancies. TOP TEN QUESTIONS What is liver NETs? How often do NETs spread? Is it expected that NETs will eventually spread? If the primary tumor was already removed, do you now call this liver NET or do you still refer to it by the primary site of origin – and why? How is this different from liver cancer? What causes NETs to spread? Is there anything that is done to cause NET tumors to spread? Is there anything that can be done to keep them from spreading? How do you determine if surgery is an option? What is involved in evaluating metastases? What scans or labs are needed? How do you decide what the “tumor burden” is? How do you weigh the grade or ki67? How do you weigh tumor size? Is there a cut-off for tumor size or the number of tumors that is too much to operate? How does one decide between surgery versus other options? How often can surgery or other treatments be done? How safe is liver surgery? How do you approach surgery for someone with liver tumors who also has tumors in the tail versus the head of the pancreas? When someone has had a Whipple surgery and later is found to have tumors in the liver, what are the options? What advances in the field are you most excited about? RESOURCES LACNETS Surgery Resources WATCH: LACNETS Surgery Playlist DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Back to the supporters page Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

Introducción NETs - La Presentación NETs de Elevador DescargarLa Tarjeta NET Intro La tarjeta NET Intro se puede completar digital o físicamente. (NOTA: Todos los recursos marcados con * están disponibles únicamente en Inglés) ¿QUÉ ES LA PRESENTACIÓN NETS DE ELEVADOR? La “Presentación NETs de Elevador” es una forma de presentarte. La razón por la que se llama de “Elevador" es porque debe ser lo suficientemente breve para poder decirla durante un viaje en elevador. Definimos una “Presentación NETs de Elevador” como una sinopsis de dos oraciones de tus NETs, que puedes comunicar en 30 segundos o menos. Si estuvieras en un elevador con un experto en NETs y solo tuvieras 30 segundos, la “Presentación NETs de Elevador” sería la introducción ideal, es concisa e ilustra claramente las características más importantes que se necesitan saber sobre tu condición. Esta es tu Introducción NETs, la mejor forma de presentar rápidamente el historial de tus NETs. La “Presentación NETs de Elevador” consta de dos oraciones y contiene la información descrita en las secciones 2 a 6, de la página 1 de NET VITALS. ORACIÓN #1: 1. Tu relación con NETs: Si vives con NETs, puedes comenzar la oración con: “Estoy viviendo con…”. “Me diagnosticaron…”. Si eres cuidador o ser querido de alguien que vive con NETs, puedes comenzar la oración con: “Mi cónyuge/hijo/padre/pariente/amigo/otro pariente vive con…”. “Mi cónyuge/hijo/padre/pariente/amigo/otro pariente fue diagnosticado con…”. Nota: Porque creemos que las palabras tienen poder, no aconsejamos identificarte como paciente o decir que estas enfermo. En su lugar, alentamos el uso de "Estoy viviendo con" o "Me diagnosticaron" o "Me diagnosticaron tal año con..." o incluso "Tengo...". Algunas personas incluso dicen "Estoy viviendo bien con..." porque da el mensaje de que las personas con NETs pueden tener una vida plena. 2. Diferenciación tumoral: Esto es "bien diferenciado" o "poco diferenciado". Se refiere a qué tan anormales se ven las células bajo el microscopio, en comparación con las células sanas circundantes 3. Grado del tumor: Puede ser grado 1, 2 o 3. El grado se refiere a la rapidez con la que se dividen las células tumorales. Si conoces tu ki-67 puedes agregarlo, ya que determina el grado del tumor. El ki-67 lo puedes encontrar en el reporte de patología, estos reportes se realizan cada vez que se extrae tejido de tu cuerpo, generalmente por medio de una biopsia o una cirugía. Es importante aclarar que el grado es diferente a la etapa o estadio, estas ultimas se refieren a qué tanto se ha desplazado el cáncer desde el sitio original del tumor. Es fácil confundir grado con etapa, pero en realidad dicen cosas muy diferentes. El público en general está familiarizado con la estatificación, porque es una forma común de describir un cáncer y da una idea de la prognosis de una persona. Sin embargo, es importante recordar que con el Cáncer Neuroendocrino, la etapa 4 no significa lo mismo que la etapa 4 de otros tipos de cáncer. Tenga en cuenta que los NETs pulmonares no están clasificados por grado, se clasifican en: Carcinoma Típico, Carcinoma Atípico, Carcinoma Neuroendocrino de Células Grandes y Carcinoma de Células Pequeñas. Los Feocromocitomas y los Paragangliomas tampoco se clasifican por grado. Vea esta infografía detallada* del podcast NETWise de NETRF sobre los NETs de pulmón Nuestros recursos de NETs de Pulmón se pueden encontrar aquí* NETWise Infographic Stage, Differentiation & Grade, courtesy of Neuroendocrine Tumor Research Foundation - Download Here 4. Estado funcional del tumor: Puede ser funcional o no funcional. Esto significa específicamente si los tumores producen hormonas (funcionales) o no producen hormonas (no funcionales) y no es indicación de la presencia de síntomas, ya que los síntomas pueden ser producidos por una variedad de razones. 5. Sitio de origen del tumor y metástasis: El sitio de origen es donde se origina el Tumor Primario y es el que define el tipo de NETs (NETs Pancreáticos (pNETs), NETs de Intestino Delgado, NETs de Pulmón, NETs de Colon, etc.) Metástasis es cualquier otro lugar (órgano diferente al Sitio Primario) en donde se encuentren mas tumores del mismo tipo que el Tumor Primario (por ejemplo en el hígado, los huesos, etc.) El sitio de origen será siempre el mismo, aún después de haber extirpado el tumor primario e incluso al no tener ya evidencia de la condición. Una de las razones por las que identificar el sitio de origen (Tumor Primario) es importante, es que le permite a tu equipo médico determinar y evaluar las opciones de tratamiento disponibles y aplicar las más adecuadas para cada caso. 6. Año en el que recibiste el diagnóstico. Este es opcional. ORACIÓN #2: La oración #1 es la base principal. Una vez que hayas dominado la oración #1, entonces (y solo entonces) estarás listo para agregar la oración #2. A la mayoría de nosotros nos resulta más fácil la oración #2 porque estamos familiarizados con los tratamientos y los procedimientos hemos recibido. La oración #2 consiste en eso, es un resumen breve de tus cirugías y tratamientos. La clave aquí es ser conciso. Estos son ejemplos de la oración #2: “A mi esposo lo operaron y le están dando un análogo de somatostatina (lanreotida u octreotida), terapia dirigida al hígado y PRRT” “Me hicieron una resección intestinal en Diciembre del 2022 y me están dando inyecciones Lanreotida, 120mg cada 28 días” ¡Ahí está! Tu historial en una breve Introducción NETs de dos oraciones, en 30 segundos o menos. Si bien puede parecer simple, sabemos que construir tu “Presentación NETs de Elevador” puede presentar ciertos retos. Además, se necesita algo de trabajo y práctica para poder pronunciar tu “Presentación NETs de Elevador” cómodamente. ¡Escríbela, tenla a mano y practica, practica, practica ! Mientras mas lo repitas, más cómodo te sentirás al decirlo y, en poco tiempo, lo podrás decir de una manera muy natural. ¿CUÁLES SON LOS BENEFICIOS DE APRENDER LA “PRESENTACIÓN NETS DE ELEVADOR”? Al aprender a "hablar NET" estarás en la misma página que un experto en NETs. Al decir tu “Presentación NETs de Elevador”, estás comunicando los elementos críticos que los expertos o tu equipo médico necesitan saber para tomar decisiones de tratamiento. Es importante que CONOZCAS Y COMPRENDAS TU CONDICIÓN y no dependas únicamente de tu equipo médico para eso. Aprender a hablar NET te ayuda a saber qué información o tratamientos son relevantes para tu caso. Al participar en reuniones educativas, podrás interpretar y entender mejor la información. Al buscar ensayos clínicos * , es posible que te ayude a determinar cuales son los mas apropiados para ti. Podrás comunicar los elementos esenciales de tus NETs de manera concisa, clara y eficiente. Comunicar los elementos críticos de la condición de una manera eficaz, nos permite tener una mejor utilización del tiempo y esto nos da una mejor oportunidad de hablar sobre tratamientos o de obtener respuestas a nuestras preguntas. Ya sea en un grupo de apoyo, con otras personas viviendo con NETs, con tu equipo médico o al conocer a un experto en NETs en una conferencia, la “Presentación NETs de Elevador” te ayudara a comunicar clara y eficazmente toda la información importante de tu condición, contenida también en tus NET VITALS*. ¿QUÉ NO DEBE ESTAR EN TU NET INTRO? Las palabras tienen poder. Desalentamos el uso de las palabras “Paciente” o “Enfermo” al referirnos a nuestra persona o a nuestros seres queridos. Preferimos el uso de palabras que empoderen y que muestren que nos vemos como personas completas y que no somos definidos por una enfermedad. Ten en cuenta que tu “Presentación NETs de Elevador’ no es lo mismo que tu historia. Hay momento y lugar para contar la historia de tu diagnóstico y de el impacto personal que ha causado. La “Presentación NETs de Elevador” no reemplaza tu historia, es una habilidad diferente, con un propósito diferente. ¡El conocimiento es poder! En esta montaña rusa, donde a veces podemos sentir que todo esta fuera de control, esto es algo que podemos controlar. Aprender tu “Presentación NETs de Elevador” te ayuda a comunicarte en el idioma de los expertos de NETs. Al cerrar las brechas de conocimiento y comprender los términos y conceptos fundamentales de NET, podemos ser mejores pacientes, cuidadores, promotores o defensores. ¡¡Crea tu “Presentación NETs de Elevador” y aprendamos juntos a hablar NET!! DescargarLa Tarjeta NET Intro La tarjeta NET Intro se puede completar digital o físicamente. *Original site translated by Michel DeQuevedo from NETs Mexico . Recursos Si no está seguro de lo qué significan los términos anteriores o de cómo encontrar la diferenciación, el grado o el ki-67 en su informe patológico, le recomendamos los siguientes recursos: Infografía NETWise de NETRF "Etapa, diferenciación y grado"* Episodio 1 del podcast NETWise de NETRF: Lo que tienes que saber sobre los NETs * Seminario web: NET VITALS (a partir de 14:20 minutos) * Seminario web de patología * a cargo de la Dra. Sue Chang (a partir de las 36:43) Video: Manejo de Síntomas * por la Dra. Del Rivero (habla de tumores funcionales y manejo del síndrome carcinoide) NOTA: NET Intro es un documento solo para uso personal. LACNETS no lo envía ni lo recopila. Es un documento que debe completar y llevar a su cita con el médico. Este documento está destinado únicamente a fines informativos y educativos y no reemplaza el asesoramiento médico profesional. Siempre consulte con su médico o proveedor de atención médica.

<< Back Additional Resources WATCH "Understanding Alpha & the Evolving PRRT Landscape" with Dr. Udhayvir Singh Grewal https://www.youtube.com/watch?v=_dE7__jhf9I Download Presentation Slides >>> "2024 Updates on Clinical Trials in Neuroendocrine Tumors" with Dr. Heloisa Soares - April 25, 2024 - LACNETS Patient Educational Event https://www.youtube.com/watch?v=Cdk8uoqKWe0 "Navigating Clinical Trials: Expectations vs Realities" with Taymeyah Al-Toubah, MPH - August 2023 LACNETS Patient Educational Event https://www.youtube.com/watch?v=CXW71vedhIw "The Latest in NET Clinical Trials" - 2023 LACNETS Patient Education Conference https://www.youtube.com/watch?v=h0MFa7jcR4k "Clinical Trials: Why, What & How" - 2023 LACNETS Patient Education Conference https://www.youtube.com/watch?v=Kf3p_j5tFVU "Patient Story & Understanding Clinical Trial Terminology" - 2020 LACNETS Symposium https://www.youtube.com/watch?v=B7XStrrQ6TI "Update on NET Clinical Trials" with Dr. Heloisa Soares - March 2023 LACNETS Educational Event https://www.youtube.com/watch?v=HHtDAQzDj9E "How Clinical Practice Has Been Changed by Clinical Trials in the Last 10 Years" by Dr. Enrique Grande (Credit: INCA) https://www.youtube.com/watch?v=lFyrU7idFUA In this 2022 recording for INCA, Dr. Enrique Grande, MD, PhD, MSc, gives a snapshot of NET research, how clinical trials inform clinical practice, and highlights key trials. "Practice Changing Research in NETS" by Prof. Jonathan R. Strosberg, President of NANETS (Credit: INCA) https://www.youtube.com/watch?v=wWdJfxX5eDs In this 2022 recording for INCA, Prof. Strosberg discusses the current NET clinical trials. "What is the Role of Patients in Trial Design and Efficacy" by Prof. Michael Michael (Credit: INCA) https://www.youtube.com/watch?v=JM1K7ZnXlCo In this 2022 recording for INCA, Prof. Michael discusses the gaps in current NET research and the role of patients in clinical trials design. LISTEN Visit the podcast episode page for more resources >>> Visit the podcast episode page for more resources >>> READ "Why Participate in Clinical Trials?" Clinical Trials Glossary "How to Prepare for Clinical Trials" Info Sheet Glossary: Common Terms in Clinical Trials Navigating Clinical Trials: Expectations vs Realities - Slides from August 19, 2023 LACNETS Educational Event

<< Go Back to NCF Events Page No registration required. HOW TO JOIN THE VIRTUAL LUNCHEON Submit your general questions for the Live Q&A on YouTube OR Facebook via chat. Click Here to Join on YouTube Stream Click Here to Join on Facebook Live “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — who present on topics relevant to neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join with their lunch break. Live sessions are recorded and will be available afterward. ABOUT JAYDIRA DEL RIVERO, MD Endocrinologist & Medical Oncologist National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page

<< Back Targeted Therapies Oral Targeted Therapies STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Antibody Drug Conjugate (ADC) Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors ZL-1310 (DLL3-targeted ADC) in DLL3+ Tumors DLL-3 DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms